INCHEON, South Korea, Jan. 26, 2022 /PRNewswire/ -- Cancer is among the leading causes of death in many countries and is progressively becoming a bigger burden on societies. One of the main challenges of developing therapies to fight this deadly disease is that drugs should target cancer cells exclusively and have as few side effects as possible. Among the many candidate compounds currently under study, the combination of boron dipyrromethene (BODIPY) with metal–organic macrocycles (MOCs) and metal–organic frameworks (MOFs) shows great potential not only to fight cancer effectively, but to also help researchers understand the disease better.